UNLABELLED: Growth hormone may be associated with the development of colorectal cancer directly and/or indirectly via increased serum level of insulin-like growth factor (IGF-I). Regular physical activity can decrease insulin resistance and modulates IGF-I production. A common polymorphism in the GH1 gene, rs2665802, was previously shown to be associated with lower IGF-I levels and decreased colorectal cancer (CRC) risk. We investigated the association of this polymorphism and physical activity with colorectal cancer risk in a case-control study. METHODS: The analysis includes 3,041 (1,402 cases and 1,639 controls) participants in the Molecular Epidemiology of Colorectal Cancer study, a population-based case-control study in Northern Israel. Analysis was carried out separately in two sets. The first set included 1,248 subjects (625 cases, 623 controls), and the second validation set consisted of 1,793 subjects (777 cases, 1,016 controls). RESULTS: No association was found between the studied polymorphism and CRC risk. However, evaluation of gene environment interactions revealed an interaction between leisure time physical activity and the GH1 polymorphism, which was consistent in both sets (P(interaction) = 0.005). The genotype AA was associated with decreased risk of CRC among individuals who did not engage in any such activity (odds ratio, 0.76; 95% confidence interval, 0.52-0.98), whereas the same genotype was marginally associated with increased risk among individuals who reported physical activity (odds ratio, 1.38; 95% confidence interval, 0.98-1.94). CONCLUSIONS: We found that the A allele of the rs2665802 polymorphism is associated with reduced risk of CRC only among physically inactive individuals, indicating an interaction between physical activity and the growth hormone/IGF-I system. A replication of the observed findings and further investigation of the underlying mechanism is warranted.
UNLABELLED: Growth hormone may be associated with the development of colorectal cancer directly and/or indirectly via increased serum level of insulin-like growth factor (IGF-I). Regular physical activity can decrease insulin resistance and modulates IGF-I production. A common polymorphism in the GH1 gene, rs2665802, was previously shown to be associated with lower IGF-I levels and decreased colorectal cancer (CRC) risk. We investigated the association of this polymorphism and physical activity with colorectal cancer risk in a case-control study. METHODS: The analysis includes 3,041 (1,402 cases and 1,639 controls) participants in the Molecular Epidemiology of Colorectal Cancer study, a population-based case-control study in Northern Israel. Analysis was carried out separately in two sets. The first set included 1,248 subjects (625 cases, 623 controls), and the second validation set consisted of 1,793 subjects (777 cases, 1,016 controls). RESULTS: No association was found between the studied polymorphism and CRC risk. However, evaluation of gene environment interactions revealed an interaction between leisure time physical activity and the GH1 polymorphism, which was consistent in both sets (P(interaction) = 0.005). The genotype AA was associated with decreased risk of CRC among individuals who did not engage in any such activity (odds ratio, 0.76; 95% confidence interval, 0.52-0.98), whereas the same genotype was marginally associated with increased risk among individuals who reported physical activity (odds ratio, 1.38; 95% confidence interval, 0.98-1.94). CONCLUSIONS: We found that the A allele of the rs2665802 polymorphism is associated with reduced risk of CRC only among physically inactive individuals, indicating an interaction between physical activity and the growth hormone/IGF-I system. A replication of the observed findings and further investigation of the underlying mechanism is warranted.
Authors: Ann Chao; Cari J Connell; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Eugenia E Calle; Vilma E Cokkinides; Michael J Thun Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Libby M Morimoto; Polly A Newcomb; Emily White; Jeannette Bigler; John D Potter Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert Journal: N Engl J Med Date: 2005-05-26 Impact factor: 91.245
Authors: K Steindorf; W Jedrychowski; M Schmidt; T Popiela; A Penar; A Galas; J Wahrendorf Journal: Eur J Cancer Prev Date: 2005-08 Impact factor: 2.497
Authors: J G Regensteiner; E J Mayer; S M Shetterly; R H Eckel; W L Haskell; J A Marshall; J Baxter; R F Hamman Journal: Diabetes Care Date: 1991-11 Impact factor: 19.112
Authors: Elizabeth C LeRoy; Jason H Moore; Chengcheng Hu; María Elena Martínez; Peter Lance; David Duggan; Patricia A Thompson Journal: Hum Genet Date: 2011-01-11 Impact factor: 4.132
Authors: Tamuno Alfred; Yoav Ben-Shlomo; Rachel Cooper; Rebecca Hardy; Cyrus Cooper; Ian J Deary; Tom R Gaunt; David Gunnell; Sarah E Harris; Meena Kumari; Richard M Martin; Avan Aihie Sayer; John M Starr; Diana Kuh; Ian N M Day Journal: PLoS One Date: 2012-01-10 Impact factor: 3.240
Authors: Colinda C J M Simons; Leo J Schouten; Roger W L Godschalk; Manon van Engeland; Piet A van den Brandt; Frederik J van Schooten; Matty P Weijenberg Journal: Sci Rep Date: 2015-09-18 Impact factor: 4.379
Authors: Su Yon Jung; Thomas Rohan; Howard Strickler; Jennifer Bea; Zuo-Feng Zhang; Gloria Ho; Carolyn Crandall Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240
Authors: Iker Alegria-Lertxundi; Carmelo Aguirre; Luis Bujanda; Francisco Javier Fernández; Francisco Polo; José M Ordovás; M Carmen Etxezarraga; Iñaki Zabalza; Mikel Larzabal; Isabel Portillo; Marian M de Pancorbo; Leire Palencia-Madrid; Ana M Rocandio; Marta Arroyo-Izaga Journal: PLoS One Date: 2019-12-10 Impact factor: 3.240